Global Multiple Sclerosis Drugs Market Research Report 2021 Featuring Biogen, Novartis, Roche, Bayer HealthCare, Pfizer., Merck & Co, Sanofi, Teva Pharm, GSK and Acorda Therapeutics – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Multiple Sclerosis Drugs Global Market Report 2021: COVID-19 Growth and Change to 2030” report has been added to ResearchAndMarkets.com’s offering.
The global multiple sclerosis drugs market is expected to grow from $21.27 billion in 2020 to $22.04 billion in 2021 at a compound annual growth rate (CAGR) of 3.6%. The market is expected to reach $25.95 billion in 2025 at a CAGR of 4%.
Major players in the multiple sclerosis drugs market are Biogen, Novartis, Roche, Bayer HealthCare, Pfizer Inc., Merck & Co. Inc., Sanofi, Teva Pharmaceutical Industries Ltd., GlaxoSmithKline and Acorda Therapeutics Inc.
The multiple sclerosis drugs market consists of sale of multiple sclerosis drugs and related services. Multiple sclerosis (MS) is an autoimmune disease where the immune system attacks the protective fat layer called myelin, around the nerve fibers and causes problems with muscle control, vision and other body functions. It is a disease that affects brain, spinal cord and the optic nerves resulting in loss of balance, coordination and compromised vision. The disease can result in long term disability.
The multiple sclerosis drugs market covered in this report is segmented by drug class into immunomodulators, immunosuppressants, interferons, others. It is also segmented by distribution channels into hospital pharmacy, retail pharmacy, and online stores and by route of administration into oral drugs and, parenteral drugs.
The high cost of drugs to treat multiple sclerosis (MS) restricts the growth of multiple sclerosis drugs market. The MS is a cureless disease with high chances of disability and requires lifelong treatment. Despite the heavy competition among the drug companies, the cost of MS drugs is high, increasing the overall cost of treatment.
The companies operating in the multiple sclerosis drugs market often have to work towards reducing the cost of these drugs to justify its cost-effectiveness to its consumers. The high cost of drugs, which are required lifelong negatively affects the growth of the multiple sclerosis drugs market.
The growth of multiple sclerosis drugs market is aided by the support from government as well as non-government organization. The government and non-government organizations fund several schemes and programs to offer their support to enhance the quality of life of people affected with multiple sclerosis (MS).
For instance, in 2019, the government of Alberta in partnership with the department of Economic Development, Trade and Tourism in Canada invested $1million towards the Canadian Prospective Cohort Study to Understand Progression in Multiple Sclerosis (CanProCo) to support the research and innovations to enhance understanding and treatment for MS disease. CanProCo is an initiative to consolidate the efforts of nearly 50 MS researchers from various disciplines across Canada.
The initiative was further funded by the Canada Brain Research, Biogen Canada and the MS Society of Canada, as well as Hoffmann-La Roche Limited (Roche Canada) to raise a total of $10 million. Appropriate financial support from the government and non-government organizations boosts the growth of multiple sclerosis drugs market.
The companies are rapidly intensifying their efforts to focus on new product launches to cater to the rising demands for MS drugs. The multiple sclerosis requires a lifelong treatment, which increases the overall cost of treating a patient. In order to provide better and effective treatment companies in the multiple sclerosis market are developing drugs specific to the treatment of multiple sclerosis.
Following the trend, in 2019, FDA approved Novartis’ Mayzent (siponimod) and EMD Serono’s Mavenclad (cladribrine) for the treatment of relapsing remitting multiple sclerosis (RRMS), and active secondary progressive multiple sclerosis (SPMS). Both the drugs were launched as an easy-to-consume oral drug.
Key Topics Covered:
1. Executive Summary
2. Multiple Sclerosis Drugs Market Characteristics
3. Multiple Sclerosis Drugs Market Trends and Strategies
4. Impact Of COVID-19 On Multiple Sclerosis Drugs
5. Multiple Sclerosis Drugs Market Size and Growth
5.1. Global Multiple Sclerosis Drugs Historic Market, 2015-2020, $ Billion
5.1.1. Drivers Of the Market
5.1.2. Restraints On the Market
5.2. Global Multiple Sclerosis Drugs Forecast Market, 2020-2025F, 2030F, $ Billion
5.2.1. Drivers Of the Market
5.2.2. Restraints On the Market
6. Multiple Sclerosis Drugs Market Segmentation
6.1. Global Multiple Sclerosis Drugs Market, Segmentation by Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
- Immunomodulators
- Immunosuppressants
- Interferons
- Others
6.2. Global Multiple Sclerosis Drugs Market, Segmentation by Distribution Channels, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
- Hospital Pharmacy
- Retail Pharmacy
- Online Stores
6.3. Global Multiple Sclerosis Drugs Market, Segmentation by Route Of Administration, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
- Oral Drugs
- Parenteral Drugs
7. Multiple Sclerosis Drugs Market Regional and Country Analysis
7.1. Global Multiple Sclerosis Drugs Market, Split by Region, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
7.2. Global Multiple Sclerosis Drugs Market, Split by Country, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
Companies Mentioned
- Biogen
- Novartis
- Roche
- Bayer HealthCare
- Pfizer Inc.
- Merck & Co. Inc.
- Sanofi
- Teva Pharmaceutical Industries Ltd.
- GlaxoSmithKline
- Acorda Therapeutics Inc.
- Actelion Pharmaceutical
- EMD Serono
- AbbVie Inc.
- Betaseron
- CinnoVex
For more information about this report visit https://www.researchandmarkets.com/r/jy7ohv
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
